BioVie Upsizes Best-Efforts Offering to ~$75M at $1.33/Share, Adding ThinkEquity as Placement Agent

summarizeSummary

BioVie amended its S-1 to upsize a best-efforts offering to ~$75 million at $1.33 per share, a 10% discount to market, with ThinkEquity as placement agent. The offering would be massively dilutive but is essential to fund the cash-strapped biotech through key clinical data readouts.

check_boxKey Events · Financing and Capital Events · BIVI

• Offering Upsized to ~$75M

  Amendment No. 1 increases the proposed best-efforts offering from $50 million to up to 56,390,977 shares at an assumed price of $1.33 per share, implying gross proceeds of approximately $75 million — a 50% increase from the initial S-1 filed July 17, 2026.

• Massive Dilution for Existing Holders

  If fully sold, the offering would issue 56.4 million new shares against 7.5 million currently outstanding, increasing the share count by over 7x. At the assumed $1.33 price, new investors would experience minimal immediate dilution, but existing shareholders would see their ownership severely compressed.

• Placement Agent and Terms Disclosed

  ThinkEquity LLC is named as placement agent, receiving a 6.0% cash fee and warrants to purchase 5.0% of the aggregate shares sold. The offering has no minimum and terminates September 30, 2026, meaning the company may raise significantly less than the maximum.

• Cash Runway Extension Critical

  With only $13.1 million in cash as of March 31, 2026, and a quarterly burn rate of ~$5 million, BioVie has less than three quarters of runway. Proceeds are earmarked for working capital and R&D, including two Phase 2 data readouts expected in late summer 2026.

auto_awesomeAnalysis · BIVI · Life Sciences

Facing a going-concern warning and less than eight months of cash runway, clinical-stage biotech BioVie has amended its S-1 to boost the proposed best-efforts offering from $50 million to approximately $75 million. The amendment sets an assumed price of $1.33 per share — a 10% discount to today's $1.48 — and names ThinkEquity as placement agent. If fully sold, the offering would issue 56.4 million shares, more than 7x the current outstanding count, causing extreme dilution. As of March 31, 2026, the company held $13.1 million in cash and is burning roughly $5 million per quarter; this raise is critical to fund operations through upcoming Phase 2 data readouts for Parkinson's and long COVID expected in late summer 2026. The deep discount and massive size reflect the company's distressed position, but successful execution would extend the cash runway and remove near-term bankruptcy risk.